Instil Bio Reports Q3 2025 Financial Results with Improved Net Loss of $13.6 Million

Instil Bio, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $13.6 million, a significant improvement compared to a net loss of $23.0 million in the same period last year. For the nine months ended September 30, 2025, the company recorded a net loss of $63.2 million, slightly higher than the $62.2 million loss reported for the same period in 2024. The company’s total operating expenses for the third quarter decreased to $15.0 million from $23.6 million year-over-year, primarily due to the absence of in-process research and development expenses, which were $10.0 million in the prior year.

The company’s cash and cash equivalents as of September 30, 2025, stood at $5.8 million, down from $8.8 million at the end of 2024. Instil Bio also reported $73.9 million in marketable securities and $3.4 million in long-term investments, bringing total current assets to $196.3 million, an increase from $124.5 million at the end of 2024. The company’s accumulated deficit rose to $718.3 million, reflecting ongoing investments in research and development, particularly in its lead product candidate, AXN-2510/IMM2510, a bispecific antibody targeting solid tumors.

Strategically, Instil Bio has made significant moves, including the in-licensing of bispecific antibodies from ImmuneOnco Biopharmaceuticals in August 2024. This collaboration has enabled the company to advance its clinical trials, including a Phase 1 trial for AXN-2510, which received Investigational New Drug (IND) clearance from the U.S. FDA in June 2025. The company is also pursuing additional clinical trials in China, where ImmuneOnco is conducting a Phase 2 trial of AXN-2510 in combination with chemotherapy.

Operationally, Instil Bio has undergone restructuring, resulting in a reduction of its workforce and the closure of its UK manufacturing facility. The company recorded restructuring and impairment charges of $16.6 million for the nine months ended September 30, 2025, compared to $7.1 million in the prior year. As of September 30, 2025, the company had 6,781,976 shares of common stock outstanding, an increase from 6,525,887 shares at the end of 2024, reflecting ongoing efforts to raise capital through its at-the-market offering program.

Looking ahead, Instil Bio anticipates continued net losses as it invests in the development of its product candidates. The company has approximately $83.4 million in cash, cash equivalents, restricted cash, marketable securities, and long-term investments, which it believes will be sufficient to fund its operations beyond 2026. However, the company acknowledges the uncertainty surrounding the timing and success of its clinical trials and the potential need for additional funding through equity offerings or collaborations.